WNK2 and neoplasm: Sorafenib is a multi-targeted oral multikinase inhibitor, which mainly acts on vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) to inhibit angiogenesis, as well as blocking the B-RAF and RAF1 of the mitogen-activated protein kinase in tumor cells to inhibit tumor proliferation [92,93].